Daily BriefsEquity Bottom-Up

Daily Brief Equity Bottom-Up: UBTECH ROBOTICS IPO: Bad Idea and more

In today’s briefing:

  • UBTECH ROBOTICS IPO: Bad Idea
  • A Pair Trade Between Samsung C&T and Samsung Electronics Amid Big Share Cancellation at Samsung C&T
  • Smartkarma Corporate Webinar | New Horizon Health: A Case of Successful Commercialization
  • [JD.com (JD US, SELL, TP US$48) Rating Change]: Rough Roads Ahead, DG to SELL
  • Keepers Holdings: Cycling into Good Results in Q4 2022, Good Momentum to Q1 2023
  • Asics (7936) | It’s a Marathon, Not a Sprint
  • [NIO (NIO US, BUY, TP US$13) Target Price Change]: Late Delivery of Key Models Hurts 1H23 Momentum
  • Orient Overseas Intl (316 HK): Still Not Too Late to Be Bearish
  • [Miniso(MNSO US, BUY, TP US$22) Earnings Preview]: Bring Made-In-China to the World’s Mall Economies
  • [ACM Research Inc. (ACMR US, BUY, TP US$30) TP Change]: At the Foothill of a Multi-Category Monopoly

UBTECH ROBOTICS IPO: Bad Idea

By Shifara Samsudeen, ACMA, CGMA

  • UBTech Robotics (1683374D HK) is engaged in smart service robotics solutions in China and has filed for an IPO on the Hong Kong Stock Exchange.
  • Though the company operates across a number of business segments, the growth prospects seems limited for most of these businesses.
  • UBTECH’s cashflow and liquidity also seems to be getting drained as the company needs to spend heavily on R&D and marketing to keep up with constantly evolving technology.

A Pair Trade Between Samsung C&T and Samsung Electronics Amid Big Share Cancellation at Samsung C&T

By Douglas Kim

  • Samsung C&T announced the cancellation of its entire treasury shares over the next five years. It has 24.7 million shares of common shares (accounting for 13.2% of common shares outstanding).
  • We like a pair trade between Samsung C&T (go long) and Samsung Electronics (go short). Samsung C&T’s share cancellation is likely to have a positive impact on its shares.
  • The recent sell-down of most of its shares in TSMC by Berkshire Hathaway is also likely to be viewed negatively by some investors in Samsung Electronics. 

Smartkarma Corporate Webinar | New Horizon Health: A Case of Successful Commercialization

By Smartkarma Research

For our next Corporate Webinar we are glad to welcome New Horizon Health’s CFO, Yu Gao.

In the upcoming webinar, Mr Gao will share a short company presentation after which, he will engage in a fireside chat with Smartkarma Insight Provider, Ke Yan. The Corporate Webinar will include a live Q&A session.

The Corporate Webinar will be hosted on Tuesday, 21 February 2023, 17:00 SGT.

About New Horizon Health

New Horizon Health (6606 HK) is a biotech focusing on the research, development and commercialization of molecular diagnostics for cancer screening in China and globally. New Horizon Health currently has three NMPA approved cancer screening tests: ColoClear: the only colorectal cancer screening test approved by NMPA (Class III medical device) for high-risk colorectal cancer population in China; Pupu Tube: the only self-conducted FIT test approved by NMPA (Class II medical device) for average-risk colorectal cancer population in China. It also obtained CE Mark in 2018; and UU Tube: the only self-conducted H. Pylori diagnostic test approved by NMPA (Class III medical device) in China. It also obtained CE Mark in 2022. The company also has pipeline tests, as well as many other undisclosed cancer screening tests under research development.


[JD.com (JD US, SELL, TP US$48) Rating Change]: Rough Roads Ahead, DG to SELL

By Shawn Yang

  • JD’s post-CNY recovery is slower than expected, based on our checks. We suggest JD would face an unfavourable external environment going forward due to: 1) the comeback of offline commerce; 
  • 2) PDD’s growing penetration in high-tier cities and brand products; 3) Meituan Instashopping offers faster delivery than JD.
  • We cut JD’s FY23 revenue YoY growth forecast from 13% to 11%. Our top and bottom line estimates for FY23 are (3%) and (5%) below cons. Downgrade to SELL

Keepers Holdings: Cycling into Good Results in Q4 2022, Good Momentum to Q1 2023

By Sameer Taneja

  • The Keepers Holdings (KEEPR PM) will announce its FY22 results in the second week of April 2023. Good results(>50% YoY profit)/high dividend payout(50%) have been catalysts for the share price.
  • We believe Q1 2023 business momentum will also be good, rendering the growth story intact. The company also made a very small acquisition of “Island Mixers” from Diageo Philippines. 
  • Despite the move recently, the stock trades at 9.4x/7.3x FY22/23e with 8-9% of the market cap in cash. With an attractive dividend yield of 5.3% for FY23. 

Asics (7936) | It’s a Marathon, Not a Sprint

By Mark Chadwick

  • We were too early to turn bearish on Asics. Recent stock price performance has been strong
  • Although rising inventories have yet to impact on margins, they are a potential red flag
  • The stock is not cheap at 29x PE. The long-term financial model suggests limited upside from here

[NIO (NIO US, BUY, TP US$13) Target Price Change]: Late Delivery of Key Models Hurts 1H23 Momentum

By Shawn Yang

  • We expect NIO to report 4Q22 top line of RMB 16.7bn and GPM of 13.2%, missing consensus by (4%)/(0.8ppt), primarily due to COVID-related supply-chain issues and lower ASP. 
  • We cut TP to US$ 13, due to weak momentum and the ongoing margin pressure in 1H23. We maintain BUY, as 1) intact model cycle starting from 2H23;
  • 2) the upcoming ET5 station wagon in 2H23 and the mass-market/low-end brands in 2024 will expand its scale economy, which in turn will justify the sustainability of its business model.

Orient Overseas Intl (316 HK): Still Not Too Late to Be Bearish

By Osbert Tang, CFA

  • We believe the 11.4% decline in share price of Orient Overseas International (316 HK) YTD is not sufficient to reflect the plunge in freight rate and weakened load performance.
  • Its 4Q22 average revenue/TEU of US$1,822.3 has returned to 2Q21 level; but with latest spot rate already plunged to early-2020 times, there is further downside for OOIL’s realised rate.
  • Export outlook is uninspiring as well, indicating pressure on demand. With similar ROE, OOIL only trades at 0.3x P/B in FY20, that makes its current P/B of 0.9x expensive.

[Miniso(MNSO US, BUY, TP US$22) Earnings Preview]: Bring Made-In-China to the World’s Mall Economies

By Shawn Yang

  • We expect Miniso to report C4Q22 top line, non-GAAP operating profit and GAAP net income 1.7%, (1.5%) and in-line vs. consensus. Our C1Q23 top line is 3.7% vs. the consensus; 
  • MNSO’s sustained growth driver to be bringing Made-In-China merchandises to the mall economies around the world; We re-evaluate the stock and maintain the Buy rating, with TP at US$22.
  • The downward revisions of EPADS:1) slower offline resumption pace from Covid impact in 2022, 2) rescheduled oversea expansion paces, compared to our previous update on Nov. 23rd, 2021.

[ACM Research Inc. (ACMR US, BUY, TP US$30) TP Change]: At the Foothill of a Multi-Category Monopoly

By Shawn Yang

  • We expect ACMR to report C4Q22 top-line, non-IFRS operating profit, and IFRS net income in-line, 21% and 96% vs. consensus, respectively. 
  • New SPE import limits provide ACMR with a multi category quasi-monopoly. Thus, we raise our FY23 market share estimate for ECD/wafer clean/furnace to 51%/32%/2% from prior 25%/25%/0%.
  • ACMR’s quasi-monopoly position in multiple categories sustain its long-run growth, which underlines a 58% TP increase to US$ 30 and continued status as our top hardware pick.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars